Pharmacological therapy for hypertrophic cardiomyopathy: What is the evidence for success?

European Heart Journal, Supplement

Volumn 3, Issue L, 2001, Pages

  Rydén, Lars ^a   Gadler, F ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Cardiomyopathy; Hypertrophic; Pharmacological; Symptomsevidence; Treatment

Indexed keywords

ALCOHOL; ANTIARRHYTHMIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DISOPYRAMIDE; METOPROLOL; NADOLOL; PROPRANOLOL; VERAPAMIL;

ARTICLE; CARDIOMYOPATHY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DISEASE COURSE; DOUBLE BLIND PROCEDURE; DRUG INDUCED DISEASE; HEART ARRHYTHMIA; HEART PACING; HEART VENTRICLE ARRHYTHMIA; HUMAN; HYPERTROPHIC CARDIOMYOPATHY; INOTROPISM; PATHOPHYSIOLOGY; PRIORITY JOURNAL; SINUS BRADYCARDIA; SYMPTOMATOLOGY;

EID: 0035157628     PISSN: 1520765X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1520-765X(01)90060-4     Document Type: Article

References (21)

1. Asymmetrical hypertrophy of the heart in young adults
2. The management of hypertrophic cardiomyopathy
3. Clinical course and prognosis of hypertrophic cardiomyopathy in an outpatient population
4. Impact of patient selection biases on the perception of hypertrophic cardiomyopathy and its natural history
5. Placebo effect of pacemaker implantation in obstructive hypertrophic cardiomyopathy. PIC Study Group. Pacing In Cardiomyopathy
6. Diastolic dysfunction in hypertrophic cardiomyopathy. Effect on active force generation during systole
7. Medical treatment of hypertrophic cardiomyopathy
8. Hypertrophic cardiomyopathy. Role of beta-blockers in therapy
9. A double-blind, placebo-controlled crossover trial of nadolol and verapamil in mild and moderately symptomatic hypertrophic cardiomyopathy
10. Hemodynamic studies of beta blockade in hypertrophicobstructive cardiomyopathy
11. Treatment of hypertrophic obstructive cardiomyopathy with verapamil
12. Hypertrophic cardiomyopathy. Role of calcium antagonists in therapy
13. Effect of verapamil on absolute myocardial blood flow in hypertrophic cardiomyopathy
14. The acute response of left ventricular filling dynamics to intravenous verapamil predicts the changes in exercise tolerance after oral verapamil therapy in patients with hypertrophic cardiomyopathy
15. Long-term follow-up of medical versus surgical therapy for hypertrophic cardiomyopathy: A retrospective study
16. Comparable effects of oral diltiazem and verapamil in the treatment of hypertrophic cardiomyopathy. Double-blind crossover study
17. Disopyramide in hypertrophic cardiomyopathy. Noninvasive assessment after oral administration
18. Effect of propranolol and disopyramide on left ventricular function at rest and during exercise in hypertrophic cardiomyopathy
19. Disopyramide improves the balance between myocardial oxygensupply and demand in patients with hypertrophic obstructive cardiomyopathy
20. Long-term treatment of hypertrophic cardiomyopathy with verapamil or propranolol in matched pairs of patients: Results of a multicenter study
21. Verapamil therapy: A new approach to the pharmacologic treatment of hypertrophic cardiomyopathy. Effects on exercise capacity and symptomatic status